Jason Friesen, MD
Allergy & Immunology · Eugene, ORNPI 1043379860
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $455 and has fallen 82.5% since, to $80 in 2025. That places this record below the midpoint for allergy & immunology clinicians in OR, where the typical reported total is $1,736.
Across 102 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$372
- GSK$301
- CSL Behring$188
- Sanofi$140
- Novartis$121
- Takeda Pharmaceuticals U.S.A., Inc.$121
- plus $492 from 16 others
Across 1 payment — averaging $60.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$61
What the payments were for
- Food & beverage$1,736100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $372 |
| GSK | 28 | $301 |
| CSL Behring | 8 | $188 |
| Sanofi | 7 | $140 |
| Novartis | 6 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $121 |
| Alk-abello, Inc | 1 | $64 |
| Octapharma USA, Inc. | 3 | $56 |
| Amgen(2 entities) | 2 | $47 |
| Grifols USA, LLC | 2 | $41 |
| Blueprint Medicines Corporation | 2 | $35 |
| AbbVie | 2 | $35 |
| Pharming Healthcare, Inc. | 2 | $35 |
| Biocryst US Sales Co., LLC | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Genentech USA, Inc. | 4 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $16 |
| Merck | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Pfizer | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Haegarda$120
How this compares
$1,736 in reported general payments places this provider in the 50th percentile of 33 allergy & immunology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 21 | $93,234 |
| Dupixent SyringeDupilumab | 20 | $82,468 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,565 |
| DuleraMometasone/Formoterol | 21 | $11,296 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $7,511 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $6,656 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $6,439 |
| Arnuity ElliptaFluticasone Furoate | 11 | $5,642 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,317 |
| Ipratropium Bromide | 153 | $4,057 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,020 |
| BreynaBudesonide/Formoterol Fumarate | 17 | $2,118 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,318 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,286 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $301 | $23,52342 claims |
| MerckDulera | $15 | $11,29621 claims |
| AstraZenecaSymbicort | $372 | $7,51125 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $28 | $6,65611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 33 allergy & immunology providers in Oregon.
Other allergy & immunology in Eugene
- Kraig JacobsonEugene$7K
- Maxwell LiEugene$5K
- Sarah KehlEugene$3K
- Richard BuckEugene$501
- Adam WilliamsBend$138K
- Shyam JoshiPortland$116K
- Stephen FritzHappy Valley$42K
- Anthony MontanaroPortland$25K
- Karen AnsteyPortland$20K
- Michael OsbornePortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.